Stock listing
OTC:IUGNF Imugene Ltd Stock
US listing (OTC) of Imugene Ltd · home listing ASX:IMU
Follow Imugene Ltd into a list and get an email when it puts out news.
Share price · OTC:IUGNF
$0.031 USD +0.002 (+6.9%)
Close on Nov 20, 2026
- Day range
- $0.021 – $0.031 USDNov 20, 2026
- Volume
- 12,656 sharesNov 20, 2026
- Market cap
- $17.30M USDAt the close on Nov 20, 2026 · price × 557.9M shares outstanding
- 52-week range
- $0.010 – $0.295 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $997 USDMedian day 505 shares · 27 days with no trades · last 3 months, Aug 20, 2026 – Nov 16, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:IMU · Home | $0.032 AUD | +0.001 (+3.2%) | 802,833 | $0.031 | $0.032 | $0.031 | $0.031 | Close on Nov 20, 2026 |
| OTC:IUGNF | $0.031 USD | +0.002 (+6.9%) | 12,656 | $0.021 | $0.031 | $0.021 | $0.029 | Close on Nov 20, 2026 |
| Frankfurt:ILA | €0.018 EUR | +0.001 (+2.9%) | — | €0.018 | €0.018 | €0.018 | €0.017 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 16, 2026 · OTC:IUGNF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.029 | 0.000 | 0.0% | $0.029 | $0.029 | $0.029 | 0 | |
| $0.029 | -0.008 | -22.7% | $0.029 | $0.029 | $0.029 | 588 | |
| $0.038 | -0.002 | -3.8% | $0.038 | $0.038 | $0.038 | 2,680 | |
| $0.039 | 0.000 | 0.0% | $0.039 | $0.039 | $0.039 | 0 | |
| $0.039 | 0.000 | 0.0% | $0.039 | $0.039 | $0.039 | 0 | |
| $0.039 | +0.015 | +63.9% | $0.025 | $0.039 | $0.020 | 7,269 | |
| $0.024 | 0.000 | 0.0% | $0.024 | $0.024 | $0.024 | 0 | |
| $0.024 | 0.000 | 0.0% | $0.024 | $0.024 | $0.024 | 0 | |
| $0.024 | 0.000 | 0.0% | $0.024 | $0.024 | $0.024 | 0 | |
| $0.024 | -0.038 | -61.5% | $0.024 | $0.024 | $0.023 | 30,429 | |
| $0.062 | 0.000 | 0.0% | $0.062 | $0.062 | $0.062 | 0 | |
| $0.062 | 0.000 | 0.0% | $0.062 | $0.062 | $0.062 | 0 | |
| $0.062 | +0.020 | +49.6% | $0.035 | $0.062 | $0.035 | 24,541 | |
| $0.041 | -0.019 | -31.2% | $0.041 | $0.041 | $0.041 | 4,411 | |
| $0.060 | 0.000 | 0.0% | $0.060 | $0.060 | $0.060 | 0 | |
| $0.060 | +0.002 | +3.6% | $0.060 | $0.060 | $0.060 | 2,000 | |
| $0.058 | 0.000 | 0.0% | $0.058 | $0.058 | $0.058 | 0 | |
| $0.058 | 0.000 | 0.0% | $0.058 | $0.058 | $0.058 | 0 | |
| $0.058 | 0.000 | 0.0% | $0.058 | $0.058 | $0.058 | 0 | |
| $0.058 | 0.000 | 0.0% | $0.058 | $0.058 | $0.058 | 0 | |
| $0.058 | 0.000 | 0.0% | $0.058 | $0.058 | $0.058 | 0 | |
| $0.058 | +0.021 | +55.6% | $0.020 | $0.058 | $0.020 | 931 | |
| $0.037 | +0.017 | +86.0% | $0.037 | $0.037 | $0.037 | 692 | |
| $0.020 | 0.000 | 0.0% | $0.020 | $0.020 | $0.020 | 0 | |
| $0.020 | -0.010 | -33.3% | $0.042 | $0.042 | $0.020 | 421 | |
| $0.030 | +0.020 | +200.0% | $0.037 | $0.037 | $0.030 | 2,381 | |
| $0.010 | -0.020 | -66.7% | $0.026 | $0.026 | $0.010 | 394 | |
| $0.030 | -0.013 | -30.6% | $0.028 | $0.037 | $0.028 | 793 | |
| $0.043 | +0.026 | +154.1% | $0.015 | $0.069 | $0.015 | 108,941 | |
| $0.017 | -0.008 | -32.0% | $0.028 | $0.028 | $0.017 | 15,002 | |
| $0.025 | 0.000 | 0.0% | $0.025 | $0.025 | $0.025 | 0 | |
| $0.025 | -0.003 | -10.7% | $0.019 | $0.047 | $0.019 | 40,000 | |
| $0.028 | -0.003 | -9.7% | $0.026 | $0.051 | $0.026 | 90,147 | |
| $0.031 | -0.004 | -11.4% | $0.050 | $0.050 | $0.031 | 55,000 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 0 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 0 | |
| $0.035 | +0.002 | +7.4% | $0.035 | $0.035 | $0.035 | 50,000 | |
| $0.033 | 0.000 | 0.0% | $0.033 | $0.033 | $0.033 | 0 | |
| $0.033 | -0.029 | -46.7% | $0.033 | $0.033 | $0.033 | 130,674 | |
| $0.061 | 0.000 | 0.0% | $0.061 | $0.061 | $0.061 | 0 | |
| $0.061 | +0.016 | +36.0% | $0.061 | $0.061 | $0.061 | 294 | |
| $0.045 | +0.005 | +12.5% | $0.045 | $0.045 | $0.045 | 9,000 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | 0.000 | 0.0% | $0.040 | $0.040 | $0.040 | 0 | |
| $0.040 | -0.015 | -27.3% | $0.055 | $0.055 | $0.040 | 81,799 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 294 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | +0.015 | +37.5% | $0.055 | $0.055 | $0.055 | 735 | |
| $0.040 | -0.010 | -20.0% | $0.055 | $0.055 | $0.040 | 1,617 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 0 | |
| $0.050 | +0.012 | +32.6% | $0.055 | $0.055 | $0.050 | 50,190 | |
| $0.038 | -0.022 | -37.2% | $0.038 | $0.038 | $0.038 | 1,470 | |
| $0.060 | -0.004 | -6.3% | $0.050 | $0.065 | $0.050 | 420,750 | |
| $0.064 | -0.011 | -14.2% | $0.050 | $0.070 | $0.050 | 45,000 | |
| $0.075 | -0.015 | -17.1% | $0.070 | $0.091 | $0.052 | 53,968 | |
| $0.090 | 0.000 | 0.0% | $0.090 | $0.090 | $0.090 | 0 | |
| $0.090 | -0.007 | -6.8% | $0.090 | $0.090 | $0.090 | 20,002 | |
| $0.097 | +0.021 | +27.9% | $0.097 | $0.097 | $0.097 | 1,008 | |
| $0.076 | -0.014 | -15.6% | $0.099 | $0.099 | $0.074 | 15,925 | |
| $0.090 | +0.007 | +9.1% | $0.099 | $0.099 | $0.075 | 9,375 |
Splits
1 split · OTC:IUGNF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-34 | Consolidation |
- Ticker
- OTC:IUGNF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Application for quotation of securities - IMU
Latest deck · Jul 7, 2026
Investor Presentation (July 2026)
Investor deck · 29 slides
Latest news
Imugene Receives $2.1M R&D Tax Refund
Nov 15, 2026
Closed $0.029 (0.0%) on Nov 16, 2026
Director Resignation and Committee Changes
Nov 10, 2026
Closed $0.039 (0.0%) on Nov 11, 2026
Results of 2026 Annual General Meeting
Nov 10, 2026
Closed $0.039 (0.0%) on Nov 11, 2026
AGM Presentation
Nov 10, 2026
Closed $0.039 (0.0%) on Nov 11, 2026
Imugene selected for Poster Presentation at 2026 ASH Meeting
Nov 4, 2026
Closed $0.024 (0.0%) on Nov 5, 2026
Positive amendments to Convertible Notes
Nov 2, 2026
Closed $0.024 (-61.5%) on Nov 3, 2026
Imugene Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 57 in the last 12 months · 266 in all · newest Nov 20, 2026 · oldest 2016
- Decks
- 54 decks · latest Jul 7, 2026
Where Imugene Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:IMU · Home listing | ASX | Australia | AUD |
| Stuttgart:ILA | Stuttgart | Germany | EUR |
| OTC:IUGNF · This page | OTC | United States | USD |
| Frankfurt:ILA | Frankfurt | Germany | EUR |
Valuation
Price/book 2.0× against a median of 4.5×: 4th lowest of 8 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $21.40M AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.7×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Imugene Ltd · ASX:IMU | US$11.74M | US$14.16M | n/a | n/a | n/a | 2.0× | n/a | 0.7× | n/a |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| Xintela AB · OMXSTO:XINT | US$11.88M | US$11.81M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Radiopharm Theranostics Limited · ASX:RAD | US$11.59M | US$8.85M | n/a | 4.8× | n/a | 0.7× | n/a | 0.0× | n/a |
| Aelis Farma SA · EURONEXT:AELIS | US$11.55M | US$9.09M | n/a | 4.0× | n/a | 4.5× | −308.7% | 1.9× | n/a |
| Simris Group AB Class B · OMXSTO:SIMRIS_B | US$11.54M | US$19.53M | n/a | 144× | n/a | 154× | n/a | 117× | n/a |
| Dyadic International, Inc. · NASDAQ:DYAI | US$11.51M | US$12.03M | n/a | 3.9× | n/a | n/a | −226.9% | n/a | 1.12 |
| Psyence Biomedical Ltd. · NASDAQ:PBM | US$11.33M | US$4.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.90 |
| Median of the others | US$11.68M | US$10.73M | 15.7× | 4.5× | −267.8% | 0.0× | 0.53 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.23 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.055 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Paul Hopper | Executive Chairman |
Board
| Director | Role |
|---|---|
| Paul Hopper | Executive Chairman |
| Charmaine Gittleson | Non-Executive Director |
| Jakob Dupont | Non-Executive Director |
| Kim Drapkin | Non-Executive Director |
| Michael Kotsanis | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −1.5% |
| Q4 2025 | Aug 25, 2025 | −8.8% |
| Quarter to Mar 31, 2025 | May 28, 2025 | −5.9% |
| Q2 2025 | Feb 27, 2025 | +2.8% |
| Quarter to Sep 30, 2024 | Nov 27, 2024 | +2.6% |
| Q4 2024 | Aug 30, 2024 | +15.3% |
| Quarter to Mar 31, 2024 | May 29, 2024 | −2.9% |
| Q2 2024 | Feb 28, 2024 | +4.3% |
| Quarter to Sep 30, 2023 | Oct 31, 2023 · Before open | +2.4% |
| Q4 2023 | Aug 25, 2023 · Before open | −2.8% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Apr 28, 2023 · After close | +4.0% |
| Q2 2023 | Feb 28, 2023 · After close | 0.0% |
| Q1 2023 | Nov 30, 2022 | +5.6% |
| Q4 2022 | Aug 31, 2022 · Before open | +8.3% |
| Q3 2022 | Jun 1, 2022 | −12.8% |
| Q2 2022 | Feb 27, 2022 | 0.0% |
| Q4 2021 | Aug 30, 2021 | +20.3% |
| Q2 2021 | Feb 26, 2021 | −4.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 29 slides | Jul 7, 2026 |
| Investor Presentation (March 2026) | Investor deck | 31 slides | Mar 11, 2026 |
| Technical Presentation (February 2026) | Technical | 15 slides | February 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 16 slides | Nov 13, 2025 |
| Shareholder Meeting (August 2025) | Shareholder meeting | 6 slides | Aug 20, 2025 |
| Investor Presentation (July 2025) | Investor deck | 37 slides | Jul 16, 2025 |
| Shareholder Meeting (January 2025) | Shareholder meeting | 10 slides | Jan 22, 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 18 slides | Nov 14, 2024 |
| Investor Presentation (September 2024) | Investor deck | 32 slides | September 2024 |
| Azer-cel Webinar September 2024 | Conference | 14 slides | September 2024 |
Show 50 decks
This page holds 50 of 54 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible notes (New Notes) Terms changed: convertible Buyers: CVI Investments, Inc. | Nov 2, 2026 | |
| Convertible notes (TAR Notes) Terms changed: convertible Buyers: CVI Investments, Inc. | Nov 2, 2026 | |
| Private placement of fully paid ordinary shares Closed: A$0.095 a share | Sep 1, 2026 | |
| Convertible notes (TAR Notes) and warrants Closed: A$2.1M raised · Warrants at A$0.0664 for 60 months Buyers: CVI Investments, Inc. ($2,100,000 worth of TAR Notes and 25,301,205 New Warrants) Use of proceeds: Fund Cohort 2 and new Cohort 3 (BTKi) of its Phase 1b trial, plus general administrative and working capital | Aug 27, 2026 | US$1.49M |
| Private placement of new shares with attaching options Announced: A$22.5M · A$0.33 a share · Warrants at A$0.43 Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26 | Jul 16, 2025 | US$14.67M |
| Share purchase plan of new shares with attaching options Announced: A$15M · A$0.33 a share · Warrants at A$0.43 Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26 | Jul 16, 2025 | US$9.78M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.40M | 4.97M | 11.8M | 13.0M | 7.23M | 4.13M | 4.13M | 1.84M | 1.16M | |
| Cost of revenue | 6.84M | 3.38M | 5.84M | 2.20M | 2.41M | 1.96M | 82.5K | 63.3K | 2.68K | 1.74K |
| Gross profit | -6.84M | 4.40M | 4.97M | 9.57M | 10.6M | 5.27M | 4.05M | 4.06M | 1.84M | 1.16M |
| Research and development | 50.9M | 46.7M | 86.9M | 30.9M | 36.6M | 15.4M | 9.36M | 7.61M | 4.15M | 2.47M |
| Selling, general and administrative | 32.2M | 27.8M | 59.9M | 17.8M | 12.1M | 9.44M | 5.52M | 4.78M | 1.21M | 894.1K |
| Operating income | -75.0M | -70.9M | -140.9M | -51.3M | -50.7M | -25.7M | -10.8M | -12.4M | -5.78M | -3.69M |
| Depreciation and amortization | 6.84M | 3.38M | 5.84M | 2.20M | 2.41M | 1.96M | 82.5K | 63.3K | 2.68K | 1.74K |
| EBITDA | -68.1M | -67.6M | -135.1M | -49.1M | -48.3M | -23.7M | -10.7M | -12.3M | -5.78M | -3.68M |
| Interest expense | 125.5K | 162.5K | 478.4K | 27.5K | 13.6K | 5.02K | 5.03K | 6.11K | 0 | 0 |
| Income before tax | -107.3M | -69.0M | -154.3M | -49.7M | -50.5M | -25.7M | -14.6M | -7.78M | -5.77M | -3.67M |
| Income tax | -2.00M | -4.04M | -4.62M | -11.7M | -12.6M | -7.23M | -4.13M | -4.13M | -1.84M | -1.16M |
| Net income | -105.3M | -69.0M | -149.7M | -37.9M | -37.9M | -18.5M | -10.5M | -7.78M | -3.93M | -2.51M |
| Earnings per share, basic | -0.32 | -0.32 | -0.72 | -0.01 | -0.23 | -0.13 | -0.09 | -0.00 | -0.05 | -0.04 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.63M | 21.9M | 93.1M | 153.2M | 99.9M | 29.5M | 30.1M | 19.0M | 7.82M | 4.81M |
| Short-term investments | 2.08M | 1.44M | -1 | 0 | ||||||
| Receivables | 2.38M | 10.0M | 12.6M | 12.1M | 12.8M | 6.66M | 4.19M | 4.22M | 1.91M | 1.22M |
| Inventory | 4.41M | -2.23M | -4.22M | -1.91M | -1.22M | |||||
| Current assets | 9.82M | 41.7M | 113.0M | 165.7M | 113.8M | 36.3M | 34.5M | 23.4M | 9.83M | 6.05M |
| Property, plant and equipment | 1.73M | 1.70M | 683.0K | 862.8K | 466.0K | 155.6K | 233.1K | 3.90K | 3.25K | |
| Total assets | 23.0M | 83.6M | 151.4M | 197.1M | 147.6M | 71.8M | 65.2M | 30.8M | 16.9M | 12.7M |
| Accounts payable | 5.57M | 6.84M | 5.97M | 2.34M | 4.51M | 759.7K | 1.01M | 1.48M | 288.5K | 16.2K |
| Current liabilities | 14.0M | 22.2M | 29.3M | 6.08M | 7.42M | 4.46M | 2.90M | 2.42M | 438.2K | 297.5K |
| Long-term debt | 2.58M | 985.5K | 985.5K | 985.5K | ||||||
| Total debt | 6.30M | 10.7M | 2.19M | 553.5K | 673.4K | 271.0K | 69.3K | 1.11M | ||
| Total liabilities | 14.0M | 38.6M | 33.1M | 7.44M | 8.90M | 6.79M | 5.40M | 3.48M | 1.44M | 1.28M |
| Shareholders' equity | 9.01M | 45.0M | 118.3M | 189.6M | 138.7M | 65.0M | 59.8M | 27.3M | 15.5M | 11.4M |
| Shares outstanding | 326.1M | 218.7M | 208.5M | 6.28B | 165.8M | 137.2M | 119.8M | 3.58B | 77.6M | 61.4M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -44.9M | -75.6M | -101.7M | -29.8M | -30.7M | -13.1M | -10.1M | -7.91M | -4.51M | -2.67M |
| Capital spending | -5 | -14.5M | -7.07M | 0 | -257.7K | -5.45M | -1.49M | -128.4K | -3.33K | -2.03K |
| Free cash flow | -44.9M | -90.0M | -108.8M | -29.8M | -30.9M | -18.6M | -11.6M | -8.04M | -4.51M | -2.68M |
| Cash from investing | -4.35M | -12.7M | -7.25M | 9.63K | -414.2K | -5.48M | -1.52M | 247.4K | -412.9K | -2.34K |
| Cash from financing | 30.0M | 17.4M | 49.4M | 83.0M | 101.4M | 18.0M | 22.7M | 18.8M | 7.93M | 5.93M |
| Dividends paid | -77.9M | -6.01M | -17.9M | -20.9M | 0 | |||||
| Share buybacks | -2.67M | -1.32M | -2.74M | -5.04M | -6.15M | -125.6K | -1.80M | -1.44M | -848.1K | -320.7K |
| Change in cash | -19.3M | -71.2M | -60.0M | 53.3M | 70.4M | -619.7K | 11.1M | 11.2M | 3.01M | 3.23M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Change of Director's Interest Notice x2 - KD & JD | Nov 20, 2026 | Ownership change notice | ASX |
| Application for quotation of securities - IMU | Nov 19, 2026 | Financing | ASX |
| Final Director's Interest Notice - LR | Nov 18, 2026 | Ownership change notice | ASX |
| Notification of cessation of securities - IMU | Nov 18, 2026 | Notification letter | ASX |
| Imugene Receives $2.1M R&D Tax Refund | Nov 15, 2026 | Financing | ASX |
| Director Resignation and Committee Changes | Nov 10, 2026 | Management or board change | ASX |
| Results of 2026 Annual General Meeting | Nov 10, 2026 | Meeting outcome | ASX |
| AGM Presentation | Nov 10, 2026 | Other filings | ASX |
| Imugene selected for Poster Presentation at 2026 ASH Meeting | Nov 4, 2026 | Operations update | ASX |
| Positive amendments to Convertible Notes | Nov 2, 2026 | Financing | ASX |
Show 200 filings
This page holds 200 of 258 filings. Open Filings
Cap table
Built by 6ix from Imugene Ltd’s releases · as of Sep 1, 2026
- Common shares
- 554,067,948
- Fully diluted
- 554,067,948
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 554,067,948 |
Warrants and options
| Lot |
|---|
| Warrants · A$0.0664 · expire about Aug 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 554,067,948 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Charmaine Gittleson | Non-Executive Director · Since at least Nov 12, 2026 |
| Jakob Dupont | Non-Executive Director · Since at least Nov 12, 2026 |
| Josep Tabernero | President of ESMO · Nov 4, 2026 – Nov 11, 2026 · Past |
| Kim Drapkin | Non-Executive Director · Since at least Nov 12, 2026 |
| Lesley Russell | Non-Executive Director · Nov 11, 2026 – Nov 11, 2026 · Past |
| Michael Kotsanis | Non-Executive Director · Since at least Nov 12, 2026 |
| Paul Hopper | Executive Chairman · Since at least Nov 12, 2026 |
| Prasad S. Adusumilli | Director · Nov 4, 2026 – Nov 11, 2026 · Past |
| Yuman Fong | Chair of the Department of Surgery · Nov 4, 2026 – Nov 11, 2026 · Past |
Log in to ask 6ix AI your own questions about Imugene Ltd.